Cargando…
Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatment
BACKGROUND: Ticagrelor is a first-line drug for the treatment of acute ST elevation myocardial infarction (STEMI). However, approximately 20% STEMI patients taking ticagrelor exhibited a delayed response and the mechanism was still unclear. METHODS: To explore the mechanism of the poor response of t...
Autores principales: | Zhang, Xi, Zhang, Xiaolin, Tong, Fangnian, Cai, Yi, Zhang, Yujie, Song, Haixu, Tian, Xiaoxiang, Yan, Chenghui, Han, Yaling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903831/ https://www.ncbi.nlm.nih.gov/pubmed/35258452 http://dx.doi.org/10.7554/eLife.70240 |
Ejemplares similares
-
Utility of S100A12 as an Early Biomarker in Patients With ST-Segment Elevation Myocardial Infarction
por: Zhang, Xiaolin, et al.
Publicado: (2021) -
Safety and feasibility of low‐dose ticagrelor in patients with ST‐segment elevation myocardial infarction
por: Wang, Yanbo, et al.
Publicado: (2020) -
Corrigendum: Utility of S100A12 as an Early Biomarker in Patients With ST-Segment Elevation Myocardial Infarction
por: Zhang, Xiaolin, et al.
Publicado: (2022) -
Safety of Bivalirudin Combined with Ticagrelor in the Emergency PCI in Patients with Acute ST-Segment Elevation Myocardial Infarction
por: Wang, Zheng-Dong, et al.
Publicado: (2022) -
Long‐Term Ticagrelor Versus Prasugrel Pharmacodynamics in Patients With ST‐Segment–Elevation Myocardial Infarction
por: Cassese, Salvatore, et al.
Publicado: (2020)